^
    Back
    Association details:
    Biomarker:CD47 expression + EPCAM expression
    Cancer:Colorectal Cancer
    Drug:VBI-003 (CD47 inhibitor, EPCAM inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2023
    Title:

    1872 / 11 - A DLL3/CD3/CD137 trispecific T cell engager shows potent antitumor activity in small cell lung cancer models

    Published date:
    03/15/2023
    Excerpt:
    VBI‑003 has potent single agent activity in SCLC tumor models and combined synergistically with irinotecan in CRC models. Our data support further investigation of VBI‑003 as a treatment for CD47 and EpCAM expressing SCLC and CRC.
    Secondary therapy:
    irinotecan